Global Vision Announces Partnership with Israeli Reseller Dor Pharmaceutical Services

Global Vision’s proofreading technologies now available to support the growing demand from pharmaceutical companies in Israel 

Dor Logo

Montreal, CANADA, and Kfar-Saba, ISRAEL, March 18, 2015Global Vision, the world leader in the development of innovative proofreading technologies, today announced the expansion of its operations in Israel through a reseller agreement with Dor Pharmaceutical Services, a leading provider of solutions to the pharmaceutical and medical device marketplace.

The Israeli marketplace has high levels of adoption of proofreading technologies with a growth rate estimated in excess of 3% annually. Pharmaceutical and medical device companies throughout Israel, now have access to Global Vision’s complete suite of products that include text-based, pixel-based, barcode and Braille inspection solutions.

“Israel is known for its vibrant pharmaceutical and medical device industry, and we are eager to take the next step in serving this exciting market with solutions like Proofware, the world’s first web-based packaging inspection suite,” explained Reuben Malz, President of Global Vision. “By partnering with Dor Pharmaceutical Services, we can better address the requirements of pharmaceutical and medical device customers in Israel and tailor solutions that meet their specific needs.”

“At Dor Pharmaceutical Services, we pride ourselves in providing leading-edge high quality professional services for pharmaceutical and medical device companies in regulatory affairs, quality assurance, clinical trials, pharmacovigilance and labelling localisation” said Rami Mittleman, COO, Dor Pharmaceutical Services. “We are highly impressed by Global Vision solutions, their performance and reliability, and are excited to expand the adoption of these powerful technologies in the Israeli market.”

Leader in proofreading technologies for 25 years

See for yourself why 72% of all pharmaceutical companies worldwide have implemented Global Vision Solutions: Download our latest brochure.

About Dor Pharmaceutical Services

Dor Pharmaceutical Services was founded in 2011 with a clear mission: to empower the development, approval, commercialization and monitoring of safe, effective pharmaceutical products, medical devices, food supplements and cosmetics in Israel.

Dor offers sound, practical regulatory affairs, quality and labelling consulting and outsourcing services as well as comprehensive pharmacovigilance and clinical research support. These essential services enable clients to extend existing resources, expedite regulatory approvals, and meet clinical development goals, while expanding market penetration and realizing significant productivity gains and cost savings.

Based in Israel, the Dor Pharmaceutical Services team of seasoned industry professionals is focused on client goals with expertise and integrity, innovation and excellence, and a commitment to unsurpassed service and support. For more information please visit:

About Global Vision

Global Vision is the world leader in the design and delivery of Innovative Proofreading Technologies.

Our solutions are widely interoperable and have been integrated into the packaging workflows of leading consumer packaged goods companies, printing firms and over 72% of the major pharmaceutical industry worldwide.

Global Vision’s complete suite of advanced solutions featuring text-based, pixel-based, barcode and Braille inspection technologies, are designed to eliminate printed artwork and copy related errors, providing end-to-end security at every stage of the packaging workflow. All our proofreading solutions meet FDA 21 CFR Part 11 / EMA Annex 11 requirements.

Headquartered in Montreal, Canada, Global Vision has worldwide representation. For more information, please visit:


Media Contacts

Avner Dor


Dor Pharmaceutical Services

T: +972-54-5441768


Mike Spooner

Marketing Communications Manager

Global Vision

T: + 1 514.624.4422 Ext. 63






Submit a Comment

Your email address will not be published. Required fields are marked *